Meta-Analysis
Copyright ©The Author(s) 2023.
World J Clin Cases. Sep 26, 2023; 11(27): 6455-6475
Published online Sep 26, 2023. doi: 10.12998/wjcc.v11.i27.6455
Table 1 Publication bias test of major measured outcomes

No. of studies
No. of patients
Egger's test
Begg's test (continuity corrected)
LRRORRtP > |t|zP > |z|
No. LNH177991209-5.1< 0.0010.370.711
Operation time165647641.570.1390.860.392
Blood loss14489689-2.180.0501.860.063
POLS177991209-3.030.0080.040.967
R0 rate8160917051.640.1620.001.000
Complications15511703-1.670.1191.290.198
Complications (Clavien-Dindo 3-4)8244245-1.850.1620.730.462
OS15129919360.30.7670.680.499
TFS10339338-1.040.3290.360.721
Table 2 Characteristics of included comparative studies
Ref.
Year
CountryStudy design
NOS
Group
Patient (n)
AgeF/M
T stage/TNM stage(n)
Follow-up (mo)
Agarwal et al[32]2015IndiaRetrospective7LRR2444 (21-61)17/7Ⅰ: 3; Ⅱ: 10; Ⅲ: 1118 (6-34)
ORR4649 (23-70)34/12Ⅰ: 5; Ⅱ: 10; Ⅲ: 31
Feng et al[33]2019ChinaRetrospective7LRR4164 ± 1417/24Tis: 9; T1: 10; T2: 14; T3: 812 (2-93)
ORR6166 ± 1022/39Tis: 4; T1: 9; T2: 1 32; T3: 16
Itano et al[34]2015JapanRetrospective6LRR1668.1 ± 19.97/9T1: 3; T2: 1337
ORR1471.5 ± 13.29/5T1-T2: 1448
Jang et al[35]2019KoreaRetrospective7LRR5570.1 ± 8.136/19T2: 5535.2 (3-139)
ORR4465.5 ± 10.521/23T2: 4438.6 (4-160)
Nag et al[36]2019IndiaRetrospective7LRR3049.6 ± 12.827/3T1: 8; T2: 8; T3: 8; T4: 2NA
ORR3849 ± 10.123/15T1: 6; T2: 17; T3: 15; T4: 0NA
Ong et al[37]2017United StatesRetrospective6LRR62370 (61-79)442/181T1 + T2: 461; T3: 146; UKN: 16NA
ORR882587/295T1 + T2: 469; T3: 374; UKN: 39NA
Vega et al[38]2019United StatesChileRetrospective8LRR6568 (59-76)49/141T1: 14; T2: 43; T3: 8Survivors: 70.8 (95%CI: 53.6 to 87.3)
ORR19011/54T1: 5; T2: 126; T3: 39
Cao et al[46]2021ChinaRetrospective8LRR5361 (48-77)35T1b: 3; T2: 50NA
ORR6164 (39-79)47T1b: 5; T2: 56NA
Dou et al[48]2022ChinaRetrospective7LRR (PSM)30> 60: 2123T2: 9; T3: 21NA
ORR (PSM)30> 60: 1925T2: 10; T3: 20NA
Lee et al[43]2022KoreaRetrospective8LRR2071.85 ± 9.1115T1: 4; T2: 12; T3: 4NA
ORR2468.08 ± 10.6413T1: 5; T2: 16; T3: 3NA
Navarro et al[41]2020KoreaRetrospective7LRR (PSM)4366.7 ± 10.318T2: 4332 (2-125)
ORR (PSM)4365.4 ± 7.615T2: 43
Regmi et al[40]2020ChinaRetrospective7LRR20> 70y: 413T1b: 10; T2: 1021.28 (12-29)
ORR30> 70y: 319T1b: 13; T2: 1720.4 (12.25-29.50)
Huang et al[44]2022ChinaRetrospective8LRR (PSM)3558.7 ± 10.519T3: 35NA
ORR (PSM)3560.4 ± 10.618T3: 35NA
D'Silva et al[45]2021ChinaRetrospective7LRR (PSM)1268.5 ± 10.567T2: 7;T3: 921.5 (9-80)
ORR (PSM)1267.5 ± 12.887T2: 5;T3: 3
Lee et al[42]2022KoreaRetrospective8LRR (PSM)5662.0 ± 13.727T2: 5626.2
ORR (PSM)5662.5 ± 15.028T2: 56
Wang et al[39]2020ChinaRetrospective8LRR4562.6 (45-76)29Tb: 30; T2: 1538 (3-84)
ORR6165.2 (51-82)37Tb: 35;T2: 2633 (6-72)
AlMasri et al[49]2020United StatesRetrospective8LRR23566.1 ± 11.864I: 24; II: 78; III: 133NA
ORR44565.8 ± 11.2294I: 29; II: 114; III: 302NA
Cho et al[47]2022KoreaRetrospective7LRR (PSM)1969.9 ± 9.111T2: 1926
ORR (PSM)1966.7 ± 7.87T2: 1970
Table 3 Perioperative outcomes of included comparative studies
Ref.
Group
Pts
No. LNH
R0 margin(n)
Operation time (min)
Blood loss (mL)
POLS
Complications
Complications(Clavien-Dindo 3-4)
Agarwal et al[32]LRR2412.5 ± 5.4NA270 (180-340)200 (100-850)5 (3-16)3NA
ORR4612.9 ± 5.4NA240 (180-360)275 (100-800)5 (3-17)8NA
Feng et al[33]LRR415 ± 333137 ± 92358 ± 3905 ± 33NA
ORR615 ± 347168 ± 51386 ± 39111 ± 56NA
Itano et al[34]LRR1612.6 ± 3.1NA368 ± 73152 ± 909.1 ± 1.61NA
ORR1410.2 ± 4.0NA352 ± 75777 ± 39221.6 ± 9.03NA
Jang et al[35]LRR557.6 ± 3.4NA231.0 ± 95.2225.1 ± 328.65.8 ± 5.374
ORR449.9 ± 6.8NA252.5 ± 76.1310.5 ± 260.99.5 ± 4.863
Nag et al[36]LRR3011.9 ± 5.230286.5 ± 71.6158.6 ± 85.76.4 ± 3.150
ORR3812.7 ± 4.237274.2 ± 96.3219.4 ± 87.79 ± 8.0125
Ong et al[37]LRR623NA484NANANANANA
ORR882NA664NANANANANA
Vega et al[38]LRR656 (0-19)62240 (120-275)300 (30-1200)4 (2-18)12NA
ORR1906 (0-27)172240 (60-600)200 (50-2000)6 (1-52)38NA
Cao et al[46]LRR536 (1-16)NA238.4257 ± 6.310.4 ± 18.6NANA
ORR618 (1-42)NA215.7256.2 ± 6.311.3 ± 18.6NANA
Dou et al[48]LRR (PSM)3010.12 ± 0.90NA328.12 ± 21.53256.74 ± 39.2110.43 ± 0.9763
ORR (PSM)307.92 ± 0.57NA245.82 ± 15.18484.36 ± 64.6714.23 ± 1.0742
Lee et al[43]LRR205.75 ± 3.5419186.60 ± 88.14320.00 ± 451.7210.95 ± 4.8222
ORR246.75 ± 4.1723231.67 ± 82.97593.75 ± 912.0412.80 ± 4.8755
Navarro et al[41]LRR (PSM)436.12 ± 5.78NA139.05 ± 97.0971.63 ± 178.776.05 ± 9.84600
ORR(PSM)4311.93 ± 7.03NA211.16 ± 91.36208.14 ± 242.16512.58 ± 5.50440
Regmi et al[40]LRR205.4 ± 3.520258.25 ± 72.50242 ± 108.56.2 ± 2.43NA
ORR305.8 ± 2.130227.00 ± 59.81401 ± 130.38.6 ± 2.36NA
Huang et al[44]LRR (PSM)358.4 ± 4.634245.0 (183.0-285.0)50.0 (50.0-150.0)6.0 (6.0-7.0)41
ORR (PSM)358.1 ± 3.933160.0 (125.0-230.0)50.0 (50.0-150.0)7.0 (6.0-8.0)62
Silva et al[45]LRR (PSM)126.5 (4-9.5)NA237.5 (120-520)300 (150-1750)4.5 (2-12)10
ORR (PSM)128.5 (4.5-14.5)NA272.5 (180-560)275 (100-1800)8 (5-32)40
Lee et al[42]LRR (PSM)564.6 ± 4.1NA171.7 ± 64.1NA5.7 ± 4.24NA
ORR (PSM)566.9 ± 4.9NA98.0 ± 53.2NA9.8 ± 4.97NA
Wang et al[39]LRR4519.8 ± 7.9NA115 ± 32.5100 ± 25.43.5 ± 1.93NA
ORR6117.3 ± 5.7NA100 ± 20.4200 ± 45.65.6 ± 2.78NA
AlMasri et al[49]LRR2356.5 ± 14.6195NANA7.0 ± 13.0NANA
ORR4456.7 ± 13.5348NANA8.8 ± 10.9NANA
Cho et al[47]LRR (PSM)195.3 ± 6.6NA218.9 ± 145.0NA8.4 ± 5.940
ORR (PSM)197.3 ± 5.5NA316.8 ± 80.3NA14.4 ± 6.020